EUVIMEDEUVIMED entdecken
Crossref

Comparison of NAFLD , MAFLD and MASLD characteristics and mortality outcomes in United States adults

Rui Song, Zhao Li, Yingzhi Zhang, Jiahe Tan, Zhiwei Chen iD

Liver International · 2024-04 · 44 (4) · 1051-1060

DOI: 10.1111/liv.15856 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 31.01.2024. Verfasst von Rui Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Metabolic Diseases. Die Arbeit wurde bisher 107-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: the First Batch of Key Disciplines on Public Health in Chongqing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Following the classification of metabolic dysfunction‐associated fatty liver disease (MAFLD), non‐alcoholic fatty liver disease (NAFLD) has recently been redefined again as metabolic dysfunction‐associated steatotic liver disease (MASLD). However, the distinctions in characteristics and mortality outcomes between NAFLD, MAFLD and MASLD remain unclear.

Methods

We analysed data from 7519 participants in the third National Health and Nutrition Examination Surveys of United States (US) and their linked mortality until 2019. Survey weight‐adjusted multivariable Cox proportional model was used to study the mortality over three terms.

Results

The prevalence of NAFLD, MAFLD and MASLD was 18.5%, 19.3% and 20.8%, respectively. Most individuals with NAFLD (94.5%) or MAFLD (100%) can be classified as MASLD, while a relatively low percentage of those with MASLD were also diagnosed with either NAFLD (84.1%) or MAFLD (92.7%). During a median follow‐up of 26.9 years, both MAFLD and MASLD were associated with increased risk of all‐cause mortality (adjusted hazard ratio [aHR] 1.18, 95% CI 1.04–1.33 and 1.19, 1.06–1.34, respectively), this association was mainly observed in NAFLD−/MASLD+ subgroups. NAFLD was not associated with all‐cause mortality. However, all three terms were associated with an increased risk of all‐cause mortality in individuals with advanced fibrosis (aHR: 1.71–1.81). Subgroup analyses showed that higher risk of all‐cause mortality for both MAFLD and MASLD were observed among older adults (≥65 year), non‐Hispanic whites and those without diabetes.

Conclusions

Both MASLD and MALFD were linked to higher all‐cause mortality risk, but MASLD identified a greater number of individuals compared to MAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseMetabolic DiseasesHumansAgedWhite

Stichwörter der Autor:innen

MAFLDMASLDNAFLDNHANES IIImortality

Autor:innen und Institutionen

  • Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chon…
  • Department of Gastroenterology, The Seventh People's Hospital of Chongqing, Chongqing, China.
  • Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

ORCID-Profile: Zhiwei Chen

Förderung

  • the First Batch of Key Disciplines on Public Health in Chongqing

Zitieren

APA

Song, R., Li, Z., Zhang, Y., Tan, J., & Chen, Z. (2024). Comparison of NAFLD , MAFLD and MASLD characteristics and mortality outcomes in United States adults. Liver International, 44(4), 1051-1060. https://doi.org/10.1111/liv.15856

Vancouver

Song R, Li Z, Zhang Y, Tan J, Chen Z. Comparison of NAFLD , MAFLD and MASLD characteristics and mortality outcomes in United States adults. Liver International. 2024;44(4):1051-1060. doi:10.1111/liv.15856

BibTeX
@article{Song2024,
  author = {Song, Rui and Li, Zhao and Zhang, Yingzhi and Tan, Jiahe and Chen, Zhiwei},
  title = {Comparison of NAFLD , MAFLD and MASLD characteristics and mortality outcomes in United States adults},
  journal = {Liver International},
  year = {2024},
  volume = {44},
  number = {4},
  pages = {1051--1060},
  doi = {10.1111/liv.15856}
}
Kostenlos starten →